The disclosure provides an injectable ganaxolone formulation comprising ganaxolone sulfobutyl ether cyclodextrin and water. The injectable ganaxolone formulation optionally includes a surfactant and a pH modifier. The ganaxolone and sulfobutyl ether cyclodextrin may be in an inclusion complex. The disclosure also provides a lyophilized powder of the ganaxolone/ sulfobutyl ether cyclodextrin formulation that may be reconstituted in water for injection. The disclosure provides a method of treating a patient having a seizure disorder stroke or traumatic brain injury comprising administering an effective amount of the injectable ganaxolone formulation comprising ganaxolone sulfobutyl ether cyclodextrin and water. The disclosure also provides combination methods in which the injectable ganaxolone/ sulfobutyl ether cyclodextrin formulation is administered in combination with at least one additional active agent.
